Leucid Bio

Lyell Immunopharma

This biopharmaceutical company develops chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies and solid tumours.

T-CURX

This biotech company develops non-viral CAR-T cell therapies to treat patients with leukaemia, lymphoma and solid tumours.

Verismo Therapeutics

This company develops chimeric antigen receptor therapies for patients with solid tumours and B-cell lymphomas.

Swarm Oncology

This biotechnology company develops personalised T cell therapies for patients with advanced solid cancers to achieve long-term remission.

OverT Bio

This company develops engineered cell therapies and genetic screening platforms to treat patients with solid tumour cancers.

A2 Biotherapeutics

This company develops logic-gated T-cell therapies to treat patients with solid tumours by selectively targeting cancer cells while sparing healthy tissue.

Waypoint Bio

This company develops cell therapies for solid tumours using a spatial biology and machine learning platform to assist patients with difficult-to-treat cancers.

Caribou Biosciences

This biopharmaceutical company develops genome-edited allogeneic cell therapies to treat patients with hematologic malignancies and other human diseases.